Poxel Announces Its Participation at Investor and Scientific Conferences in September
POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in September 2021.
- POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in September 2021.
- Thomas Kuhn, CEO, will present the company, and Poxel management team members will be available for one-on-one virtual meetings.
- Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
- Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.